QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) An erratum has been published Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Leslie, E. M. Articles by Cole, S. P. C. Search for Related Content PubMed PubMed Citation Articles by Leslie, E. M. Articles by Cole, S. P. C.

ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION

Structural Requirements for Functional Interaction of Glutathione Tripeptide Analogs with the Human Multidrug Resistance Protein 1 (MRP1)

Departments of Pharmacology and Toxicology (E.M.L., S.P.C.C.) and Chemistry (R.J.B.) and the Cancer Research Laboratories (E.M.L., R.G.D., S.P.C.C.), Queen's University, Kingston, Ontario, Canada

Received September 4, 2002; accepted October 16, 2002.

	Abstract

Top Abstract Materials and Methods Results Discussion References

 
The human multidrug resistance protein 1 (MRP1) is a primary active transporter of reduced (GSH) and oxidized glutathione, as well as GSH-, glucuronate-, and sulfate-conjugated organic anions. In addition, the transport of certain MRP1 substrates is stimulated by the presence of GSH. To evaluate the structural features of GSH required for interaction with the protein, we investigated the ability of a series of GSH analogs to enhance GSH stimulatable transport of [³H]estrone 3-sulfate (E₁SO₄). We found that substitution of the -Glu residue with Gly, -Asp, and -Glu resulted in complete loss of transport stimulation. In contrast, substitution of Gly with Glu or -Ala resulted in only a partial loss of stimulatory activity. E₁SO₄ transport activity sur-passed GSH-stimulated levels in the presence of tripeptides in which Cys was substituted with the hydrophobic amino acids Leu, Phe, and homo-Phe. Moreover, polar substitutions of Cys did not enhance transport to the same extent as nonpolar substitutions of comparable size. -Glu-Leu-Gly was 1.6-fold more effective than GSH in stimulating E₁SO₄ uptake, and kinetic analysis indicated this was due to an increased V_max. In addition, this tripeptide was shown to be a competitive inhibitor of apigenin-stimulated GSH transport (K_i value of 14 µM), confirming that it either interacts with the same site on MRP1 as GSH or that the binding of the two tripeptides is mutually exclusive. These data provide insight into the architecture of the GSH binding domain of MRP1.

View larger version (14K): [in this window] [in a new window]   Fig. 1. Chemical structures of GSH and its -Glu- and Gly-substituted derivatives examined in this study.

The human 190-kDa multidrug resistance protein MRP1 (gene symbol ABCC1) is a member of subfamily "C" of the ATP-binding cassette superfamily of transport proteins and was originally identified on the basis of its elevated expression in multidrug-resistant lung cancer cells (Cole et al., 1992; Leslie et al., 2001a). In transfected cell lines, MRP1 confers resistance to a broad range of natural product drugs as well as the folic acid antimetabolite methotrexate, and certain arsenic and antimony oxyanions (Cole et al., 1994; Grant et al., 1994; Chen et al., 1999; Hipfner et al., 1999; Hooijberg et al., 1999). In addition to its ability to confer drug resistance in tumor cells, MRP1 is a primary active transporter of GSH and glutathione disulfide, as well as GSH-, glucuronate-, and sulfate-conjugated organic anions of physiological and toxicological relevance (Hipfner et al., 1999; Paulusma et al., 1999; Leslie et al., 2001a). Potential physiological substrates include a mediator of inflammation, leukotriene C₄, and the estrogen conjugate E₁SO₄ (Leier et al., 1994; Loe et al., 1996; Qian et al., 2001). Substrates of toxicological importance include the endo and exo GSH conjugates of the mycotoxin aflatoxin B₁ and the GSH conjugate of the lipid peroxidation product 4-hydroxy trans-2-nonenal (Loe et al., 1997; Renes et al., 2000). Certain unmodified xenobiotics such as vincristine and aflatoxin B₁ are also transported by MRP1 but their transport requires the presence of GSH (Versantvoort et al., 1995; Zaman et al., 1995; Loe et al., 1996, 1997, 1998; Rappa et al., 1997). GSH has also recently been reported to enhance or be required for MRP1-mediated transport of the conjugated steroid E₁SO₄, the -O-glucuronide of the carcinogenic 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL), and the glucuronide conjugate of the anticancer agent etoposide (Sakamoto et al., 1999; Leslie et al., 2001b; Qian et al., 2001). There is convincing evidence that GSH is cotransported with unmodified compounds, whereas this does not seem to be the case for at least two conjugated MRP1 substrates, E₁SO₄ and NNAL-O-glucuronide.

In addition to enhancing the transport of some MRP1 substrates, GSH increases the potency of several compounds to inhibit conjugated organic anion transport, despite the fact that GSH alone is a poor inhibitor (Leslie et al., 2001c). For example, vincristine and the Ca²⁺ channel antagonist verapamil are poor inhibitors of MRP1-mediated leukotriene C₄ transport alone but in the presence of GSH, their inhibitory potency is increased more than 20-fold (Loe et al., 1996, 1998, 2000). Furthermore, it has been demonstrated that the binding of two MRP1-specific modulating agents, agosterol A and LY475776, is dependent on GSH (Ren et al., 2001; Mao et al., 2002). Interestingly, xenobiotics such as verapamil and several dietary flavonoids (including the flavone apigenin), stimulate GSH transport by MRP1 up to 4-fold without being transported themselves (Loe et al., 2000; Leslie et al., 2001c, 2003). Overall, the interaction between MRP1 and GSH is complex and presently is not well understood. However, it has been proposed that MRP1 contains at least one bipartite, if not multipartite, binding pocket to accommodate the hydrophobic and hydrophilic moieties of conjugated and unconjugated MRP1 substrates in combination with GSH (Loe et al., 1996; Heijn et al., 1997; Borst et al., 2000; Evers et al., 2000; Ito et al., 2001).

We have recently reported that ophthalmic acid, an endogenously formed GSH analog that contains an -aminobutyrate (Abu) residue in place of cysteine, can support the transport of NNAL-O-glucuronide almost as well as GSH (Leslie et al., 2001b). Moreover, ophthalmic acid is as effective as GSH in supporting the photolabeling of the protein by the MRP1-specific modulator LY475776 (Mao et al., 2002). Thus, in contrast to GSH conjugation to electrophilic substrates by GSTs, the presence of a cysteinyl thiol group is not required for GSH-stimulated substrate transport by MRP1 or for the action of GSH-dependent MRP1 modulators. In the present study, we have extended our investigations to identify the structural features of GSH that enable it to modulate MRP1 transport activity. Thus, we have measured the ability of a series of GSH analogs and derivatives to substitute for GSH in enhancing the transport of [³H]E₁SO₄ as a model GSH-stimulatable substrate of MRP1.

	Materials and Methods

Top Abstract Materials and Methods Results Discussion References

 
Materials. [6,7-³H]Estrone sulfate (43 Ci mmol^-1) and [glycine 2-³H]GSH (50 Ci mmol^-1) were purchased from PerkinElmer Life Sciences (Guelph, ON, Canada). The tripeptides -Glu-Cys-Gly, -Asp-Cys-Gly, -Glu-Ala-Gly, -Glu-Val-Gly, -Glu-Leu-Gly, -Glu-Ser-Gly, -Glu-Thr-Gly, -Glu-Phe-Gly, -Glu-Met-Gly, -Glu-Tyr-Gly, -Glu-Trp-Gly, -Glu-benzyl-Cys-Gly (S-benzyl-GSH), and -Glu-homo-Phe-Gly were custom synthesized by Queen's University Peptide Synthesis Laboratory (Kingston, ON, Canada). The purity of the peptides was confirmed to be 95% by high-performance liquid chromatography and their identities were confirmed by matrix-assisted laser desorption ionization mass spectroscopy. -Glu--Abu-Gly (ophthalmic acid), -Glu-Gly-Gly, -Glu-Cys--Ala (homo-GSH), and Gly-Cys-Gly were from Bachem California (Torrance, CA). E₁SO₄, GSH, S-methyl-GSH (-Glu-methyl-Cys-Gly), S-ethyl-GSH (-Glu-ethyl-Cys-Gly), oxidized -Glu-Cys-Glu, S-(p-azidophenacyl)-GSH, ATP, AMP, acivicin, and DTT were from Sigma Diagnostics Canada (Mississauga, ON, Canada). The disulfide of -Glu-Cys-Glu was prereduced with a 10-fold molar excess of DTT at 21°C for 30 min before its addition to the transport assay described below. These tripeptides and their molecular volumes (obtained using the View-erPro 4.2; Accelrys, Princeton, NJ) are listed in Table 1.

Membrane Vesicle Preparation and Immunoblotting. Membrane vesicles were prepared as described with modifications (Loe et al., 1996). Briefly, cells were homogenized in buffer containing 250 mM sucrose/50 mM Tris pH 7.5/0.25 mM CaCl₂ and protease inhibitor cocktail tablets (Complete, mini EDTA free) (Roche Diagnostics, Laval, QC, Canada). Cells were disrupted by N₂ cavitation (5-min equilibration at 200 psi) and then released to atmospheric pressure and EDTA added to 1 mM. The suspension was centrifuged at 800g at 4°C for 15 min and the supernatant was layered onto a 10 ml of 35% (w/w) sucrose/1 mM EDTA/50 mM Tris, pH 7.4, cushion. After centrifugation at 100,000g at 4°C for 1 h, the interface was removed and placed in a 25 mM sucrose/50 mM Tris, pH 7.4, solution and centrifuged at 100,000g at 4°C for 30 min. The membranes were washed with buffer (250 mM sucrose, 50 mM Tris pH 7.4) and then resuspended by vigorous syringing with a 27-gauge needle. Protein concentration was determined using a Bradford assay (Bio-Rad, Mississauga, ON, Canada), and aliquots of membrane vesicles were stored at -70°C. Relative levels of MRP1 protein in membrane vesicles were determined by immunoblot analysis as described previously, with the human MRP1-specific monoclonal antibody QCRL-1 (Hipfner et al., 1996).

[³H]E₁SO₄ Transport Studies. A stably transfected HeLa cell line expressing wild-type MRP1 cDNA was used as the source of MRP1-enriched membrane vesicles for all E₁SO₄ uptake assays, which were carried out by a rapid filtration method as described previously (Ito et al., 2001; Qian et al., 2001; Conrad et al., 2002). Briefly, membrane vesicles (2.5 µg of protein) were incubated for 3 min at 37°C in a total reaction volume of 50 µl containing ATP or AMP (4 mM), MgCl₂ (10 mM), ± GSH or GSH analog (1 mM, unless otherwise indicated), DTT (10 mM, with the exception of assays containing the disulfide of -Glu-Cys-Glu for which DTT was omitted), creatine phosphate (10 mM), creatine kinase (100 µg ml^-1), and [³H]E₁SO₄ (300 nM, 50 nCi). All GSH analogs were dissolved in Tris sucrose buffer (250 mM sucrose/50 mM Tris pH 7.5) except when prevented by solubility limits. Thus, -Glu-benzyl-Cys-Gly (S-benzyl-GSH) was dissolved in dimethyl sulfoxide (final concentration <1%) and S-(p-azidophenacyl)-GSH was dissolved in acetonitrile (final concentration <2.5%). The total reaction mix was removed and placed in 800 µl of Tris sucrose buffer and filtered through glass fiber filters (type A/E), washed twice, and radioactivity quantitated by liquid scintillation counting. Transport in the presence of AMP was subtracted from transport in the presence of ATP and reported as ATP-dependent [³H]E₁SO₄ uptake. Apparent K_m and V_max values of ATP-dependent [³H]E₁SO₄ uptake were determined as described above except transport was measured over a range of E₁SO₄ concentrations (0.07–12 µM; 100 nCi) in the presence of 1 mM GSH or -Glu-Leu-Gly for 1 min, a time for which E₁SO₄ uptake was known to be linear.

[³H]GSH Transport Studies. The multidrug-resistant small cell lung cancer cell line H69AR, which expresses 4- to 8-fold higher levels of MRP1 than the transfected HeLa cells, was used as the source of MRP1-enriched membrane vesicles for [³H]GSH uptake assays. Uptake was measured as described for [³H]E₁SO₄ except the total reaction volume was 60 µl. To minimize GSH catabolism by -glutamyl transpeptidase during transport, membranes (20 µg of protein per reaction) were preincubated with 0.5 mM acivicin at 37°C for 10 min (Loe et al., 1998). Uptake assays were carried out in the presence of 30 µM apigenin (dissolved in dimethyl sulfoxide to a final concentration of 0.7%) for 20 min at 37°C (Leslie et al., 2001a,c, 2003). Initial inhibition experiments were carried out in the presence of -Glu-Leu-Gly (0, 10, 30, 100, and 300 µM) at an initial concentration of 100 µM [³H]GSH (120 nCi). Subsequently, the mode of -Glu-Leu-Gly mediated inhibition of apigenin stimulated [³H]GSH transport was determined by measuring [³H]GSH uptake over eight different substrate concentrations (10–1500 µM, 120–240 nCi) in the presence and absence of -Glu-Leu-Gly (60 µM) (Leslie et al., 2003). Eadie-Hofstee plots were generated, using GraphPad Prism software (GraphPad Software Inc., San Diego, CA), and a K_i value was calculated.

	Results

Top Abstract Materials and Methods Results Discussion References

 
Effect of -Glu Substitutions on GSH-Stimulated [³H]E₁SO₄ Uptake by MRP1. To determine whether the -Glu residue in GSH (-Glu-Cys-Gly) was important for the ability of the tripeptide to enhance E₁SO₄ uptake by MRP1, uptake was measured using membrane vesicles prepared from MRP1-transfected HeLa cells in the presence of three GSH analogs containing a modified -Glu residue. Consistent with previous reports, GSH (1 mM) stimulated E₁SO₄ uptake approximately 6- to 7-fold compared with basal uptake in the absence of this tripeptide (Figs. 2, 4, and 5) (Qian et al., 2001; Conrad et al., 2002). Shortening the -Glu side chain or removing it altogether by substituting -Glu with -Asp and Gly, respectively, resulted in tripeptides with side chain molecular volumes 94 and 76% that of GSH (Table 1). However, neither tripeptide stimulated E₁SO₄ uptake to levels above the low basal uptake observed in the absence of GSH (Fig. 2A). Furthermore, a tripeptide in which the Glu residue (and therefore the molecular volume) was maintained, but the site of attachment was switched from the -carboxylate to the -carboxylate (-Glu-Cys-Gly) also did not stimulate E₁SO₄ uptake (Fig. 2A). These observations indicate that both the molecular volume and orientation of the -Glu moiety of GSH are critical for interaction with MRP1.

View larger version (16K): [in this window] [in a new window]   Fig. 2. Effect of GSH and GSH analogs containing -Glu and Gly substitutions on [3H]E1SO4 uptake by MRP1-enriched cell membrane vesicles. Membrane vesicles (2.5 µg of protein) were incubated for 3 min at 37°Cin transport buffer with [3H]E1SO4 (300 nM, 50 nCi). Results are expressed as a percentage of GSH-stimulated [3H]E1SO4 uptake. Columns represent means of triplicate determinations (± S.D.) in a typical experiment. A, incubations were carried out in the absence (open column) or presence (shaded columns) of GSH (1 mM), or analogs with -Glu substitutions: -Glu-Cys-Gly (1 mM), -Asp-Cys-Gly (1 mM), or Gly-Cys-Gly (1 mM) as indicated. In the experiment shown the basal and GSH-stimulated levels of [3H]E1SO4 uptake were 2.4 ± 0.98 and 12.2 ± 0.32 pmol mg-1 min-1, respectively. B, incubations were carried out in the absence (open column) or presence (shaded columns) of GSH (1 mM), or analogs with Gly substitutions: -Glu-Cys--Ala (1 mM), oxidized -Glu-Cys-Glu (1 mM), or reduced -Glu-Cys-Glu (1 mM) as indicated. The basal and GSH-stimulated levels of [3H]E1SO4 uptake were 6.7 ± 0.3 and 49 ± 4.1 pmol mg-1 min-1, respectively.

View larger version (18K): [in this window] [in a new window]   Fig. 4. Effect of GSH and GSH analogs containing nonaromatic Cys substitutions on [3H]E1SO4 uptake by MRP1-enriched membrane vesicles. Membrane vesicles (2.5 µg of protein) were incubated for 3 min at 37°C in transport buffer with [3H]E1SO4 (300 nM, 50 nCi). Results are expressed as a percentage of GSH-stimulated [3H]E1SO4 uptake. Columns represent means of triplicate determinations (± S.D.) in a typical experiment. Similar results were obtained in at least one additional experiment. A, incubations were carried out in the absence (open column) or presence (shaded columns) of GSH (1 mM), or analogs with nonaromatic, nonsulfur substitutions: -Glu-Gly-Gly, -Glu-Ala-Gly, -Glu-Abu-Gly, -Glu-Val-Gly, -Glu-Leu-Gly, -Glu-Ser-Gly, or -Glu-Thr-Gly (all at 1 mM), as indicated. Substitutions with amino acids of a more polar nature are indicated with hatched columns. The basal and GSH-stimulated levels of [3H]E1SO4 uptake were 6.8 ± 0.6 and 46.3 ± 4.4 pmol mg-1 min-1, respectively. B, uptake assays were carried out in the absence (open column) or presence (shaded columns) of GSH (1 mM), or analogs with the sulfur containing alkyl substitutions in the Cys position: -Glu-Met-Gly, S-methyl GSH, or S-ethyl GSH (all at 1 mM) as indicated. The basal and GSH-stimulated levels of [3H]E1SO4 uptake were 3.5 ± 0.6 and 21 ± 1.4 pmol mg-1 min-1, respectively.

View larger version (24K): [in this window] [in a new window]   Fig. 5. Effect of GSH and GSH analogs containing aromatic Cys substitutions on [3H]E1SO4 uptake by MRP1-enriched membrane vesicles. A, chemical structures of Cys-substituted GSH derivatives with aromatic side chains examined in this study. B, membrane vesicles (2.5 µg of protein) were incubated for 3 min at 37°C in transport buffer with [3H]E1SO4 (300 nM, 50 nCi). Uptake assays were carried out in the absence (open column) or presence (shaded columns) of GSH (1 mM), or the aromatic Cys substitutions -Glu-Phe-Gly, -Glu-homoPhe-Gly, -Glu-benzyl-Cys-Gly, -Glu-Tyr-Gly, or -Glu-Trp-Gly (all at 1 mM) as indicated. Results are expressed as a percentage of GSH-stimulated [3H]E1SO4 uptake. The basal and GSH-stimulated levels of [3H]E1S O4 uptake were 7.3 ± 0.9 and 50.4 ± 4.5 pmol mg-1 min-1, respectively. C, uptake assays were carried out as in B except that S-(p-azidophenacyl)-GSH was added at 100 µM. The basal and GSH-stimulated levels of [3H]E1SO4 uptake were 2.6 ± 2.9 and 43.2 ± 4.5 pmol mg-1 min-1, respectively. Bars represent means of triplicate determinations (± S.D.) in a typical experiment.

Effect of Gly Substituted GSH Derivatives on [³H]E₁SO₄ Uptake by MRP1. To investigate the importance of the Gly residue for GSH interaction with MRP1, [³H]E₁SO₄ uptake was measured in the presence of -Glu-Cys--Ala and the oxidized and reduced forms of -Glu-Cys--Glu. Levels of E₁SO₄ uptake were approximately 80% of those observed in the presence of GSH when Gly was substituted with -Ala (-Glu-Cys--Ala) (molecular volume 225 ų), an amino acid derivative that has one more methylene group than Gly, which increases the molecular volume of this side chain from 3 to 15 ų (Fig. 2B). The bulky -Glu-Cys--Glu was tested in its oxidized/disulfide form and also after it had been reduced with DTT. The reduced form stimulated uptake to levels that were approximately 30% of those in the presence of GSH, whereas oxidized -Glu-Cys--Glu had no stimulating effect at all (Fig. 2B). This observation suggests that at least in the presence of E₁SO₄, there is a limit to the bulk of the side chain at the Gly position of GSH that can be accommodated by the GSH binding site of MRP1.

Effect of Nonaromatic and Nonsulfur-Containing Cys Substitutions on GSH-Stimulated [³H]E₁SO₄ Uptake by MRP1. We have previously reported that ophthalmic acid, an analog of GSH-containing Abu (side chain molecular volume 28 ų), instead of Cys (side chain molecular volume 36 ų), can support the transport of NNAL-O-glucuronide (Leslie et al., 2001b) and photolabeling by LY475776 (Mao et al., 2002), demonstrating that the thiol group of the Cys residue is not required for the effective interaction of GSH with MRP1. We now show that ophthalmic acid also stimulates E₁SO₄ transport to levels that are approximately 90% of those observed in the presence of GSH (Fig. 4A). Other GSH analogs containing nonaromatic nonsulfur-containing substituents in place of Cys (Fig. 3A) also stimulated [³H]E₁SO₄ uptake but with differing abilities. Reducing the Abu by a single methylene group through substitution with Ala, which has a side chain of molecular volume less than 50% of Cys, still resulted in a peptide (-Glu-Ala-Gly) capable of supporting E₁SO₄ with an uptake activity approximately 65% that of GSH. Complete elimination of the side chain through substitution of Cys with Gly (-Glu-Gly-Gly) reduced E₁SO₄ transport stimulatory activity by approximately half compared with GSH (Fig. 4A).

View larger version (22K): [in this window] [in a new window]   Fig. 3. Chemical structures of the Cys-substituted GSH derivatives with nonaromatic side chains examined in this study.

E₁SO₄ uptake levels in the presence of tripeptides that contained Cys substitutions with amino acids of increasing hydrophobicity were comparable with or greater than GSH-stimulated uptake levels. Thus, transport in the presence of peptides in which Cys was substituted with Val (side chain molecular volume 42 ų) and the larger Leu (side chain molecular volume 54 ų) was approximately 100 and 160%, respectively, of that observed in the presence of GSH. In contrast, [³H]E₁SO₄ transport uptake was reduced to approximately 40 and 60%, of GSH levels in the presence of tripeptides in which the Cys residue of GSH was replaced with Ser (side chain molecular volume 23 ų) (-Glu-Ser-Gly) and Thr (side chain molecular volume 37 ų) (-Glu-Thr-Gly), respectively, both of which are more hydrophilic residues with side chains of comparable molecular volumes to Cys (Fig. 4A). These results show that both molecular volume and hydrophobicity of the amino acid side chain in the Cys position of GSH are important for interaction with the GSH binding pocket of MRP1 because there was a positive correlation between these properties and the relative ability to stimulate E₁SO₄ uptake activity.

Effect of Nonaromatic Sulfur-Containing Cys Substitutions on GSH-Stimulated [³H]E₁SO₄ Transport by MRP1. We have previously reported that short-chain S-alkyl derivatives of GSH support NNAL-O-glucuronide, vincristine, and E₁SO₄ transport by MRP1 as well as supporting the photolabeling of MRP1 by the tricyclic isoxazole modulator LY475776 (Loe et al., 1998; Leslie et al., 2001b; Qian et al., 2001; Mao et al., 2002). It was therefore of interest to examine the activity of several other tripeptides with nonaromatic S-linked substitutions that increase the steric bulk of this region of the tripeptide (Fig. 3B). Under the conditions of this study, S-methyl GSH (1 mM) (side chain molecular volume 48 ų) stimulated E₁SO₄ uptake to a level that was 1.7-fold greater than GSH (Fig. 4B) and similar to the stimulation observed with -Glu-Leu-Gly, which is of comparable molecular volume (side chain 54 ų) (Fig. 4A). The bulkier S-ethyl GSH (side chain 61 ų) was an even more potent stimulator, increasing E₁SO₄ uptake approximately 2.5-fold more than GSH (Fig. 4B). In contrast, E₁SO₄ uptake in the presence of -Glu-Met-Gly, which has the same molecular formula and volume but different molecular shape from S-ethyl GSH, was slightly less (83 ± 6%) than that in the presence of GSH (Fig. 4B). The difference in the ability of S-ethyl GSH and -Glu-Met-Gly to stimulate E₁SO₄ uptake suggests that in addition to bulk and hydrophobicity, the molecular dimensions of the amino acid side chain at this position is important for maximal stimulation of MRP1 transport activity.

Effect of Cys Substitutions with Aromatic Amino Acids on GSH-Stimulated E₁SO₄ Transport by MRP1. The ability of several Cys-substituted tripeptides with extended hydrophobic side chains to stimulate E₁SO₄ uptake to levels similar to or greater than GSH prompted us to test additional GSH analogs with bulkier, aromatic side chains at this position, including Phe, homo-Phe, benzyl-Cys, Tyr, and Trp (Fig. 5). Substitution of Cys with Phe (-Glu-Phe-Gly), which increases the molecular volume of the side chain from 36 to 74 ų resulted in a 1.3-fold increase in estrone 3-sulfae uptake compared with GSH (Fig. 5). Similarly, when the length of the alkyl side chain before the link between the peptide backbone and the aromatic substituent was increased by one methylene group, the resulting tripeptide (-Glu-homo-Phe-Gly) stimulated uptake 1.4-fold more than GSH. On the other hand, when Cys was replaced with benzyl-Cys, an amino acid with an even longer alkyl linker chain and larger molecular volume (94 ų), the resulting tripeptide (-Glu-benzyl-Cys-Gly or S-benzyl GSH) stimulated uptake to a level comparable with that in the presence of GSH (Fig. 5).

Despite the fact that -Glu-Phe-Gly stimulated E₁SO₄ uptake more than GSH, the addition of a hydroxyl group to the aromatic ring by substituting Cys with Tyr (-Glu-Tyr-Gly), which increases the side chain molecular volume to 82 ų, substantially reduced the stimulating activity of the tripeptide to only 25% that of GSH. Similarly, -Glu-Trp-Gly (Trp side chain molecular volume 100 ų), which is comparable in size with -Glu-benzyl-Cys-Gly, stimulated uptake only 2-fold above the low basal uptake level in the absence of GSH, with an activity approximately 30% that of GSH (Fig. 5). Thus, as observed for the Cys3 Ser-substituted and Cys3 Thr-substituted tripeptides, the introduction of an H-bonding polar amino acid diminished the interaction of the tripeptide with the GSH binding pocket of MRP1 even if the side chain is aromatic.

S-(p-Azidophenacyl)-GSH has been widely used for photoaffinity-labeling studies of GSH-dependent enzymes, as well as more recently of MRP1, and has a significantly larger total and side chain molecular volume (319 and 144 ų, respectively) than GSH (Seddon and Douglas, 1980; Ciaccio et al., 1996; Whalen et al., 1996; Qian et al., 2002). This compound was only testable at a maximal concentration of 100 µM because of its low solubility in the aqueous transport assay mixture. At this concentration, this tripeptide stimulated E₁SO₄ uptake 2-fold above the low level basal activity, which was comparable with the stimulation in the presence 100 µM GSH but 5-to 6-fold less than in the presence of 1 mM GSH (Fig. 5C).

Effect of -Glu-Leu-Gly on Kinetic Parameters of [³H]E₁SO₄ Uptake by MRP1. The most potent nonsulfur-containing analog of GSH, -Glu-Leu-Gly, was further characterized by determining its effect on the kinetic parameters of E₁SO₄ transport. Uptake was measured at seven different concentrations (0.7–12 µM) of [³H]E₁SO₄ in the presence of -Glu-Leu-Gly (1 mM) or GSH (1 mM), and K_m and V_max values were obtained from Eadie-Hofstee plots of the data (Fig. 6). In the presence of GSH, the K_m and V_max values for E₁SO₄ were 436 nM and 127 pmol mg^-1 min^-1, respectively. In the presence of -Glu-Leu-Gly, the K_m value was comparable at 479 nM but the V_max value was increased 1.5-fold to 192 pmol mg^-1 min^-1.

View larger version (18K): [in this window] [in a new window]   Fig. 6. Kinetic analysis of [3H]E1SO4 uptake in the presence of GSH and -Glu-Leu-Gly. E1SO4 uptake by MRP1-enriched membrane vesicles was measured at different substrate concentrations (range 0.17–12 µM) in the presence of 1 mM GSH (f) or 1 mM -Glu-Leu-Gly (F) for 1 min at 37°C. Eadie-Hofstee plots were generated and kinetic parameters determined. In the presence of GSH, the Km and Vmax values for E1SO4 were 436 µM and 127 pmol mg-1 min-1, respectively; in the presence of -Glu-Leu-Gly, the Km and Vmax values were 479 µM and 192 pmol mg-1 min-1, respectively. Data points are the means (± S.D.) of triplicate determinations in a typical experiment. Similar results were obtained in three additional independent experiments.

Modulation of Apigenin-Stimulated [³H]GSH Uptake by -Glu-Leu-Gly. To further characterize the interaction of -Glu-Leu-Gly with MRP1, the ability of this tripeptide to inhibit apigenin-stimulated [³H]GSH uptake was examined. As shown in Fig. 7A, basal [³H]GSH uptake by H69AR MRP1-enriched membrane vesicles was 42 ± 7 pmol mg^-1 min^-1, and this uptake was stimulated 5-fold to 235 ± 12 pmol mg^-1 min^-1 in the presence of apigenin (30 µM) (Fig. 7A). Apigenin-stimulated [³H]GSH uptake was reduced by -Glu-Leu-Gly in a concentration-dependent manner with approximately 60% inhibition observed at 100 µM (Fig. 7A), a concentration equal to the initial concentration of [³H]GSH in the uptake assay. The IC₅₀ value for -Glu-Leu-Gly was estimated to be 60 µM (Fig. 7A).

View larger version (17K): [in this window] [in a new window]   Fig. 7. Modulation of apigenin-stimulated [3H]GSH uptake by -Glu-Leu-Gly. [3H]GSH uptake by membrane vesicles (20 µg) prepared from H69AR cells was measured for 20 min at 37°C. A, uptake was measured at an initial [3H]GSH concentration of 100 µM (120 nCi) in the absence (open column) and presence (shaded column) of apigenin (30 µM) with -Glu-Leu-Gly indicated. Columns represent the means of triplicate determinations (± S.D.) in a typical experiment. B, uptake of [3H]GSH over a range of substrate concentrations (10–1500 µM) was measured in the presence of apigenin (30 µM) with 0 µM (•) and 60 µM () of -Glu-Leu-Gly. Symbols represent the means of triplicate determinations (± S.D.) in a typical experiment. Eadie-Hofstee plots were generated and kinetic parameters determined (inset). In the absence of -Glu-Leu-Gly, the Km and Vmax values for apigenin-stimulated GSH transport were 69 µM and 710 pmol mg-1 min-1, respectively; in the presence of -Glu-Leu-Gly, the apparent Km and Vmax values were 362 µM and 768 pmol mg-1 min-1, respectively. The Ki (-Glu-Leu-Gly) was determined to be 14 µM.

The mode of -Glu-Leu-Gly inhibition of [³H]GSH uptake was characterized by determination of kinetic parameters. The K_m and V_max values obtained from Eadie-Hofstee plots for apigenin-stimulated GSH uptake were 69 µM and 710 pmol mg^-1 min^-1, respectively. In the presence of -Glu-Leu-Gly (60 µM), the apparent K_m value for GSH uptake was increased more than 5-fold to 362 µM, whereas the V_max (768 pmol mg^-1min^-1) was similar to that in the absence of -Glu-Leu-Gly. These results indicate -Glu-Leu-Gly is a potent competitive inhibitor of apigenin stimulated [³H]GSH uptake with a K_i value of 14 µM (Fig. 7B).

	Discussion

Top Abstract Materials and Methods Results Discussion References

 
In the present study, we found that the molecular volume of the -Glu side chain in GSH and its -COOH linkage to Cys were critical for effective interaction with the GSH binding pocket of MRP1 because tripeptides in which the side chain was eliminated or shortened or in which the linkage was modified, no longer stimulated E₁SO₄ uptake. The -Glu residue has been shown to be the main binding determinant of GSH for several rat liver GST isoenzymes (Adang et al., 1988). Thus, similar to our findings with MRP1-mediated transport of E₁SO₄, -Asp-Cys-Gly was not a substrate for any of the four GST isoenzymes tested. However, in contrast to our observations with MRP1, some level of GST activity was maintained in the presence of -Glu-Cys-Gly (Adang et al., 1990). Regardless of the site of addition ( or -COOH) of the Glu residue, a free COOH group is present at the same distance from the peptide bond in -Glu-Cys-Gly and -Glu-Cys-Gly (GSH), whereas the position of the free NH₂ group is substantially different (Fig. 1). Several studies of GSTs using the decarboxylated and deaminated analogs of GSH GABA-Cys-Gly and glutaric acid-Cys-Gly, respectively) indicate that the removal of the NH₂ group reduces the catalytic efficiency of GST, whereas removal of the -COOH group eliminates enzyme activity altogether (Adang et al., 1988; Gustafsson et al., 2001). Our observation that -Glu-Cys-Gly does not stimulate E₁SO₄ transport suggests that the position of the NH₂ group and possibly the distance between the COOH and NH₂ groups are important determinants of GSH interaction with MRP1. Studies of mammalian GST isoforms indicate that the carboxylate moiety ( or ) of Glu must be present for catalysis of conjugation reactions to enable ionization of the GSH thiol group (Adang et al., 1988; Gustafsson et al., 2001). Clearly, this property is not required for GSH stimulation of E₁SO₄ transport by MRP1.

We also found that the Gly residue of GSH could be altered significantly while still retaining some level of stimulatory activity. Previous studies demonstrated that the dipeptides -Glu-Cys and Cys-Gly do not support vincristine transport by MRP1, suggesting that a tripeptide is required (Loe et al., 1998). Thus, although an amino acid is required at the Gly position, the molecular volume of the side chain is not critical for interaction with the GSH binding site of MRP1. For example, the -Glu-Cys--Ala contains an additional methylene group within the COOH terminus of this tripeptide and yet this peptide was just as effective as GSH in stimulating E₁SO₄ transport. Even -Glu-Cys--Glu-stimulated transport although only 30% as effectively as GSH. The disulfide form of -Glu-Cys--Glu was not expected to support transport of E₁SO₄ because the disulfide form of GSH (glutathione disulfide) did not (Qian et al., 2001).

Cys is commonly thought of as being the most physiologically active amino acid of GSH, and indeed, as mentioned previously, replacement of this residue results in a tripeptide that cannot be used by GSTs in conjugation reactions (Adang et al., 1990). In contrast, our studies show that it can be modified dramatically and still retain the ability to enhance E₁SO₄ transport by MRP1. Significant levels of transport stimulation were observed even with a peptide having no side chain at this position (-Glu-Gly-Gly), demonstrating that not only is the thiol group not essential for its interaction with MRP1 but also no space-filling side chain is required.

Tripeptides in which the Cys residue was replaced with residues of increasing hydrophobicity, including those with longer side chains (Val, Leu, methyl-Cys, and ethyl-Cys) and bulkier aromatic side chains (Phe, homo-Phe, and benzyl-Cys), maintained or exceeded the ability of GSH to stimulate E₁SO₄ transport. In contrast, tripeptides with polar amino acid substitutions of the Cys residue were less able to support transport, even when the substituted side chain occupied a molecular volume comparable with Cys. Thus, the conservatively substituted -Glu-Ser-Gly stimulated transport only half as effectively as GSH. Furthermore, whereas -Glu-Val-Gly stimulated transport just as well as GSH, the more polar -Glu-Thr-Gly was much less effective. Similarly, -Glu-Phe-Gly exceeded GSH in its ability to stimulate E₁SO₄ uptake, whereas -Glu-Tyr-Gly did not stimulate uptake at all. Finally, -Glu-Trp-Gly did not stimulate uptake to any extent despite the fact that a tripeptide with an equally bulky but nonpolar side chain, -S-benzyl-GSH, did so at a level similar to GSH. This is likely due to the hydrogen-bonding capabilities of the Trp indole ring (Gallivan and Dougherty, 1999) because peptides substituted with other polar amino acids such as Ser, Thr, or Tyr were also ineffective at stimulating transport. In addition, although the molecular volume of Trp is similar to benzyl-Cys, it has a very different molecular shape and therefore reduced steric complementarity could also be a factor in the poor interaction of -Glu-Trp-Gly with the GSH binding pocket of MRP1.

Of particular interest was our observation that -Glu-Met-Gly stimulated E₁SO₄ transport almost as well as GSH, whereas S-ethyl GSH, which has the same molecular formula and volume and similar overall polarity as -Glu-Met-Gly, caused a significant hyperstimulation (2.5-fold). This indicates that although the molecular volume of the side chain at the Cys position is important for GSH analog interaction with MRP1, some specificity exists with respect to the location of the sulfur atom. The importance of the location of the sulfur atom could be simply due to a change in shape of the functional group, reducing the steric complementarity, or it could be related to the optimal placement of the sulfur atom for critical bonding interactions with amino acids in the GSH binding pocket of MRP1. Overall, the lack of stimulation of E₁SO₄ uptake by Cys-substituted tripeptides with polar amino acid side chains and the hyperstimulation of uptake by Cys-substituted tripeptides with large hydrophobic side chains provides strong evidence that the Cys residue of GSH is positioned to interact with hydrophobic residues in the GSH binding region of MRP1. This is in contrast to the conjugating GSTs where the thiol group of the Cys residue typically forms hydrogen bonds with the hydroxyl group of polar residues such as Tyr or Ser in the active site of the enzyme (Dirr et al., 1994).

Kinetic analyses of [³H]E₁SO₄ uptake showed that the apparent affinity (K_m) of MRP1 for this substrate was similar in the presence of GSH or -Glu-Leu-Gly; however, the transport efficiency was 1.5-fold higher in the presence of the Leu-substituted analog. Further kinetic analyses showed that -Glu-Leu-Gly was a competitive inhibitor of apigenin-stimulated [³H]GSH transport (K_i value of 14 µM), indicating that -Glu-Leu-Gly and GSH likely bind to the same or at least overlapping sites on MRP1. The K_i value for -Glu-Leu-Gly is lower than the K_m value for apigenin-stimulated GSH uptake, which is approximately 70 µM (Leslie et al., 2003). This implies that -Glu-Leu-Gly binds MRP1 with high affinity and could potentially be a substrate for this transporter. It is also possible that -Glu-Leu-Gly binds to MRP1 with such high affinity that it may be poorly transported across the membrane. If an ordered binding mechanism occurs (i.e., the tripeptide binds first causing a conformational change in MRP1 that is required for subsequent interaction with E₁SO₄), it could be that tripeptides such as -Glu-Leu-Gly and S-ethyl-GSH have a stronger affinity for MRP1 than GSH and cause a protein conformational change more favorable for E₁SO₄ transport. We have previously proposed that GSH may stimulate transport by masking a site in MRP1 that diminishes the affinity of the protein for certain substrates (Leslie et al., 2001b). Tripeptides such as -Glu-Leu-Gly could play a similar "masking role". However, this would make it difficult to explain how -Glu-Leu-Gly competitively inhibits apigenin-stimulated GSH transport, unless the masking site overlaps with the site of GSH interaction before transport.

We have previously reported that certain short-chain S-alkyl derivatives of GSH support MRP1-mediated transport of vincristine and NNAL-O-glucuronide (Loe et al., 1998; Leslie et al., 2001b) as well as photolabeling by the MRP1-specific chemosensitizing agent LY475776 (Mao et al., 2002). However, although S-methyl GSH stimulates E₁SO₄ uptake more effectively than GSH, the same tripeptide supports NNAL-O-glucuronide uptake and LY475776 photolabeling of MRP1 approximately as well as GSH and in the case of vincristine, S-methyl GSH supports uptake to levels that are only 30% of those observed with GSH (Loe et al., 1998; Leslie et al., 2001b; Qian et al., 2001). In the current study, we have found that S-ethyl GSH is even more effective than S-methyl GSH at stimulating E₁SO₄ uptake. In contrast, this analog was less effective than S-methyl GSH in supporting vincristine uptake (Loe et al., 1998). Thus, E₁SO₄ transport is stimulated much more effectively by the S-alkyl derivatives than vincristine transport. The reason for these differences is uncertain but presumably relates to some physical properties of these substrates. Vincristine occupies a molecular volume of 615 ų, which is significantly greater than that of E₁SO₄ (239 ų), NNAL-O-glucuronide (271 ų), and LY475776 (366 ų). Thus, it is possible that the presence of vincristine within the substrate binding pocket reduces the interaction of the bulkier S-alkyl derivatives simply through steric hindrance. It follows, therefore, that even though -Glu-Leu-Gly is a potent stimulator of E₁SO₄ transport and a clear competitive inhibitor of apigenin-stimulated GSH transport, it is not necessarily expected that this tripeptide would stimulate transport or binding of other GSH-dependent MRP1 substrates to the same extent. Thus, if one envisions GSH and substrate fitting into a binding pocket with multiple binding coordinates, it may be that the significantly greater bulk of vincristine (compared with E₁SO₄) could prevent a GSH analog with a larger molecular volume from being accommodated in the same site. Studies are in progress to test this hypothesis. We conclude that in addition to molecular volume, other factors contribute to the functional interaction of GSH and its analogs with MRP1, including molecular geometry and the positioning of hydrogen bonding donor and acceptor atoms.

	Acknowledgements

 
We thank Curtis Oleschuk for helpful scientific discussions and Isabelle Létourneau for assistance with membrane vesicle preparations. We thank Maureen Rogers for assistance with manuscript preparation and submission.

	Footnotes

 
This work was supported by Grant MOP-10519 from the Canadian Institutes of Health Research. E.M.L. is the recipient of a Canadian Institutes of Health Research Doctoral Award. R.G.D. is the Stauffer Cancer Research Professor of Queen's University, and S.P.C.C. is a Canada Research Chair in Cancer Biology.

DOI: 10.1124/jpet.102.044073.

ABBREVIATIONS: GSH, glutathione; GST, glutathione S-transferase; MRP1, multidrug resistance protein 1; E₁SO₄, estrone 3-sulfate; NNAL, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol; Abu, aminobutyrate; DTT, dithiothreitol.

Address correspondence to: Dr. Susan P. C. Cole, Cancer Research Laboratories, Room 328, Botterell Hall, Queen's University, Kingston, ON, Canada, K7L 3N6. E-mail: coles{at}post.queensu.ca

	References

Top Abstract Materials and Methods Results Discussion References

 

Adang AEP, Brussee J, Meyer DJ, Coles B, Ketterer B, van der Gen A, and Mulder GJ (1988) Substrate specificity of rat liver glutathione S-transferase enzymes for a series of glutathione analogues, modified at the -glutamyl moiety. Biochem J 255: 721–724.[Medline]

Adang AEP, Brussee J, van der Gen A, and Mulder GJ (1990) The glutathione-binding site in glutathione S-transferases. Investigation of the cysteinyl, glycyl and -glutamyl domains. Biochem J 269: 47–54.[Medline]

Borst P, Evers R, Kool M, and Wijnholds J (2000) A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 92: 1295–1302.[Abstract/Free Full Text]

Chen Z, Furukawa T, Sumizawa T, Ono K, Ueda K, Seto K, and Akiyama S (1999) ATP-Dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK-104P. Mol Pharmacol 55: 921–928.[Abstract/Free Full Text]

Ciaccio PJ, Shen H, Kruh GD, and Tew KD (1996) Effects of chronic ethacrynic acid exposure on glutathione conjugation and MRP expression in human colon tumor cells. Biochem Biophys Res Commun 222: 111–115.[CrossRef][Medline]

Cole SPC, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AMV, and Deeley RG (1992) Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science (Wash DC) 258: 1650–1654.[Abstract/Free Full Text]

Cole SPC, Sparks KE, Fraser K, Loe DW, Grant CE, Wilson GM, and Deeley RG (1994) Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res 54: 5902–5910.[Abstract/Free Full Text]

Conrad S, Kauffmann H.-M., Ito K, Leslie EM, Deeley RG, Schrenk D, and Cole SPC (2002) A naturally occurring mutation in MRP1 results in a selective decrease in organic anion transport and in increased doxorubicin resistance. Pharmacogenetics 12: 321–330.[CrossRef][Medline]

Dirr H, Reinemer P, and Huber R (1994) X-ray crystal structures of cytosolic glutathione S-transferases. Implications for protein architecture, substrate recognition and catalytic function. Eur J Biochem 220: 645–661.[Medline]

Evers R, de Haas M, Sparidans R, Beijnen J, Wielinga PR, Lankelma J, and Borst P (2000) Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export. Br J Cancer 83: 375–383.[CrossRef][Medline]

Gallivan JP and Dougherty DA (1999) Cation- interactions in structural biology. Proc Natl Acad Sci USA 96: 9549–9564.

Grant CE, Valdimarsson G, Hipfner DR, Almquist KC, Cole SPC, and Deeley RG (1994) Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res 54: 357–361.[Abstract/Free Full Text]

Gustafsson A, Pettersson PL, Grehn L, Jemth P, and Mannervik B (2001) Role of the glutamyl alpha-carboxylate of the substrate glutathione in the catalytic mechanism of human glutathione transferase A1–1. Biochemistry 40: 15835–15845.[CrossRef][Medline]

Hammond CL, Lee TK, and Ballatori N (2001) Novel roles for glutathione in gene expression, cell death and membrane transport of organic solutes. J Hepatol 34: 946–954.[CrossRef][Medline]

Heijn M, Hooijberg JH, Scheffer GL, Szabo G, Westerhoff HV, and Lankelma J (1997) Anthracyclines modulate multidrug resistance protein (MRP) mediated organic anion transport. Biochim Biophys Acta 1326: 12–22.[Medline]

Hipfner DR, Almquist KC, Stride BD, Deeley RG, and Cole SPC (1996) Location of a protease-hypersensitive region in the Multidrug Resistance Protein (MRP) by mapping of the epitope of MRP-specific monoclonal antibody QCRL-1. Cancer Res 56: 3307–3314.[Abstract/Free Full Text]

Hipfner DR, Deeley RG, and Cole SPC (1999) Structural, mechanistic and clinical aspects of MRP1. Biochim Biophys Acta 1461: 359–276.[Medline]

Hooijberg JH, Broxterman HJ, Kool M, Assaraf YG, Peters GJ, Scheper RJ, Borst P, Pinedo HM, and Jansen G (1999) Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res 59: 2532–2535.[Abstract/Free Full Text]

Ito K, Olsen SL, Qiu W, Deeley RG, and Cole SPC (2001) Mutation of a single conserved tryptophan in multidrug resistance protein 1 (MRP1/ABCC1) results in loss of drug resistance and selective loss of organic anion transport. J Biol Chem 276: 15616–15624.[Abstract/Free Full Text]

Leier I, Jedlitschky G, Buchholz U, Cole SPC, Deeley RG, and Keppler D (1994) The MRP gene encodes an ATP-dependent export pump for leukotriene C₄ and structurally related conjugates. J Biol Chem 269: 27807–27810.[Abstract/Free Full Text]

Leslie EM, Deeley RG, and Cole SPC (2001a) Toxicological relevance of the multi-drug resistance protein 1, MRP1 (ABCC1) and related transporters. Toxicology 167: 3–23.[CrossRef][Medline]

Leslie EM, Deeley RG, and Cole SPC (2003) Bioflavonoid stimulation of glutathione transport by the 190 kDa multidrug resistance protein 1 (MRP1). Drug Metabol Dispos 31: 11–15.[Abstract/Free Full Text]

Leslie EM, Ito K, Upadhyaya P, Hecht SS, Deeley RG, and Cole SPC (2001b) Transport of the -O-glucuronide conjugate of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) by the multidrug resistance protein 1 (MRP1): requirement for glutathione or a non-sulfur-containing analog. J Biol Chem 276: 27846–27854.[Abstract/Free Full Text]

Leslie EM, Mao Q, Oleschuk CJ, Deeley RG, and Cole SPC (2001c) Modulation of multidrug resistance protein 1 (MRP1/ABCC1) transport and ATPase activities by interaction with dietary flavonoids. Mol Pharmacol 59: 1171–1180.[Abstract/Free Full Text]

Loe DW, Almquist KC, Deeley RG, and Cole SPC (1996) Multidrug resistance protein (MRP)-mediated transport of leukotriene C 4 and chemotherapeutic agents in membrane vesicles: demonstration of glutathione-dependent vincristine transport. J Biol Chem 271: 9675–9682.[Abstract/Free Full Text]

Loe DW, Deeley RG, and Cole SPC (1998) Characterization of vincristine transport by the 190 kDa multidrug resistance protein, MRP: evidence for co-transport with reduced glutathione. Cancer Res 58: 5130–5136.[Abstract/Free Full Text]

Loe DW, Deeley RG, and Cole SPC (2000) Verapamil stimulates glutathione transport by the multidrug resistance protein 1 (MRP1). J Pharmacol Exp Ther 293: 530–538.[Abstract/Free Full Text]

Loe DW, Stewart RK, Massey TE, Deeley RG, and Cole SPC (1997) ATP-dependent transport of aflatoxin B₁ and its glutathione conjugates by the product of the MRP gene. Mol Pharmacol 51: 1034–1041.[Abstract/Free Full Text]

Lucente G, Luisi G, and Pinnen F (1998) Design and synthesis of glutathione analogues. Il Farmaco 53: 721–735.

Mao Q, Qiu W, Weigl KE, Lander PA, Tabas L, Shepard RL, Dantzig AH, Deeley RG, and Cole SPC (2002) GSH-dependent photolabeling of multidrug resistance protein MRP1 (ABCC1) by [¹²⁵I]-LY475776: evidence of a major binding site in the COOH-proximal membrane spanning domain. J Biol Chem 277: 28690–28699.[Abstract/Free Full Text]

Paulusma CC, van Geer MA, Evers R, Heijn M, Ottenhoff R, Borst P, and Oude Elferink RPJ (1999) Canalicular multispecific organic anion transporter/multidrug resistance protein 2 mediates low-affinity transport of reduced glutathione. Biochem J 338: 393–401.

Qian YM, Grant CE, Westlake CJ, Zhang D, Lander PA, Shepard RL, Dantzig AH, Cole SPC, and Deeley RG (2002) Photolabeling of human and murine multidrug resistance protein 1 with the high affinity inhibitor [¹²⁵I]LY475776 and azidophenacyl[³⁵S]glutathione. J Biol Chem 277: 35225–35231.[Abstract/Free Full Text]

Qian YM, Song WC, Cui H.-R, Cole SPC, and Deeley RG (2001) Glutathione stimulate sulfated estrogen transport by multidrug resistance protein 1. J Biol Chem 276: 6404–6411.[Abstract/Free Full Text]

Rappa G, Lorico A, Flavell RA, and Sartorelli AC (1997) Evidence that the multidrug resistance protein (MRP) functions as a co-transporter of glutathione and natural product toxins. Cancer Res 57: 5232–5237.[Abstract/Free Full Text]

Ren XQ, Furukawa T, Aoki S, Nakajima T, Sumizawa T, Haraguchi M, Chen Z, Kobayashi M, and Akiyama S (2001) Glutathione-dependent binding of a photoaffinity analog of agosterol A to the C-terminal half of human multidrug resistance protein. J Biol Chem 276: 23197–23206.[Abstract/Free Full Text]

Renes J, de Vries EGE, Hooiveld GJEJ, Krikken I, Jansen PLM, and Muller M (2000) Multidrug resistance protein MRP1 protects against the toxicity of the major lipid peroxidation product 4-hydroxynonenal. Biochem J 350: 555–561.

Sakamoto H, Hara H, Hirano K, and Adachi T (1999) Enhancement of glucuronosyl etoposide transport by glutathione in multidrug resistance-associated protein-overexpressing cells. Cancer Lett 135: 113–119.[CrossRef][Medline]

Seddon AP and Douglas KT (1980) A photoaffinity label derivative of glutathione and its inhibition of glyoxalase I. FEBS Lett 110: 262–264.[CrossRef][Medline]

Versantvoort CHM, Broxterman HJ, Bagrij T, Scheper RJ, and Twentyman PR (1995) Regulation by glutathione of drug transport in multidrug-resistant human lung tumour cell lines overexpressing multidrug resistance-associated protein. Br J Cancer 72: 82–89.[Medline]

Whalen R, Kempner ES, and Boyer TD (1996) Structural studies of a human class glutathione S-transferase. Photoaffinity labeling of the active site and target size analysis. Biochem Pharmacol 52: 281–288.[CrossRef][Medline]

Zaman GJR, Lankelma J, van Tellingen O, Beijnen J, Dekker H, Paulusma C, Oude Elferink RPJ, Baas F, and Borst P (1995) Role of glutathione in the export of compounds from cells by the multidrug-resistance-associated protein. Proc Natl Acad Sci USA 92: 7690–7694.[Abstract/Free Full Text]

This article has been cited by other articles:

				K. Maeno, A. Nakajima, G. Conseil, A. Rothnie, R. G. Deeley, and S. P. C. Cole Molecular Basis for Reduced Estrone Sulfate Transport and Altered Modulator Sensitivity of Transmembrane Helix (TM) 6 and TM17 Mutants of Multidrug Resistance Protein 1 (ABCC1) Drug Metab. Dispos., July 1, 2009; 37(7): 1411 - 1420. [Abstract] [Full Text] [PDF]

				C. E. Grant, M. Gao, M. K. DeGorter, S. P. C. Cole, and R. G. Deeley Structural Determinants of Substrate Specificity Differences between Human Multidrug Resistance Protein (MRP) 1 (ABCC1) and MRP3 (ABCC3) Drug Metab. Dispos., December 1, 2008; 36(12): 2571 - 2581. [Abstract] [Full Text] [PDF]

				A. Rothnie, G. Conseil, A. Y. T. Lau, R. G. Deeley, and S. P. C. Cole Mechanistic Differences between GSH Transport by Multidrug Resistance Protein 1 (MRP1/ABCC1) and GSH Modulation of MRP1-Mediated Transport Mol. Pharmacol., December 1, 2008; 74(6): 1630 - 1640. [Abstract] [Full Text] [PDF]

				A. J. Slot, D. D. Wise, R. G. Deeley, T. J. Monks, and S. P. C. Cole Modulation of Human Multidrug Resistance Protein (MRP) 1 (ABCC1) and MRP2 (ABCC2) Transport Activities by Endogenous and Exogenous Glutathione-Conjugated Catechol Metabolites Drug Metab. Dispos., March 1, 2008; 36(3): 552 - 560. [Abstract] [Full Text] [PDF]

				R. G. Deeley, C. Westlake, and S. P. C. Cole Transmembrane Transport of Endo- and Xenobiotics by Mammalian ATP-Binding Cassette Multidrug Resistance Proteins. Physiol Rev, July 1, 2006; 86(3): 849 - 899. [Abstract] [Full Text] [PDF]

				T. Soga, R. Baran, M. Suematsu, Y. Ueno, S. Ikeda, T. Sakurakawa, Y. Kakazu, T. Ishikawa, M. Robert, T. Nishioka, et al. Differential Metabolomics Reveals Ophthalmic Acid as an Oxidative Stress Biomarker Indicating Hepatic Glutathione Consumption J. Biol. Chem., June 16, 2006; 281(24): 16768 - 16776. [Abstract] [Full Text] [PDF]

				A. Rothnie, R. Callaghan, R. G. Deeley, and S. P. C. Cole Role of GSH in Estrone Sulfate Binding and Translocation by the Multidrug Resistance Protein 1 (MRP1/ABCC1) J. Biol. Chem., May 19, 2006; 281(20): 13906 - 13914. [Abstract] [Full Text] [PDF]

				D. Situ, A. Haimeur, G. Conseil, K. E. Sparks, D. Zhang, R. G. Deeley, and S. P. C. Cole Mutational Analysis of Ionizable Residues Proximal to the Cytoplasmic Interface of Membrane Spanning Domain 3 of the Multidrug Resistance Protein, MRP1 (ABCC1): GLUTAMATE 1204 IS IMPORTANT FOR BOTH THE EXPRESSION AND CATALYTIC ACTIVITY OF THE TRANSPORTER J. Biol. Chem., September 10, 2004; 279(37): 38871 - 38880. [Abstract] [Full Text] [PDF]

				E. M. Leslie, A. Haimeur, and M. P. Waalkes Arsenic Transport by the Human Multidrug Resistance Protein 1 (MRP1/ABCC1): EVIDENCE THAT A TRI-GLUTATHIONE CONJUGATE IS REQUIRED J. Biol. Chem., July 30, 2004; 279(31): 32700 - 32708. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) An erratum has been published Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Leslie, E. M. Articles by Cole, S. P. C. Search for Related Content PubMed PubMed Citation Articles by Leslie, E. M. Articles by Cole, S. P. C.